Tarceva New Rx Share Doubles Since Release Of Failed Iressa Survival Study
This article was originally published in The Pink Sheet Daily
Executive Summary
New prescription share for Genentech/OSI’s oncologic jumps from about 40% to above 80% following news that AstraZeneca’s Iressa failed to demonstrate a survival benefit. Tarceva sales growth will depend on the ability to differentiate the drug’s profile from that of Iressa, OSI exec says.